Emil Lou

2 weeks ago | cancernetwork.com | Rohit Gosain |Rahul Gosain |Emil Lou

Panelists discuss how the treatment approach for pancreatic cancer typically involves a multidisciplinary strategy that combines surgery, chemotherapy, radiation therapy, and emerging targeted therapies, with a focus on improving patient outcomes through individualized care plans based on tumor characteristics and disease stage. Stay up to date on recent advances in the multidisciplinary approach to cancer.

2 weeks ago | cancernetwork.com | Rohit Gosain |Rahul Gosain |Emil Lou

Panelists discuss how next-generation sequencing (NGS) and germline testing are increasingly being used in pancreatic cancer to identify genetic mutations, guide personalized treatment decisions, and inform the use of targeted therapies, ultimately improving patient outcomes and advancing precision medicine. Stay up to date on recent advances in the multidisciplinary approach to cancer.

2 weeks ago | cancernetwork.com | Rohit Gosain |Rahul Gosain |Emil Lou

Panelists discuss how radiation therapy plays a crucial role in the treatment of pancreatic cancer, particularly in combination with surgery and chemotherapy, to manage locally advanced disease, reduce tumor size, and improve patient outcomes while also considering its potential adverse effects and optimal usage in treatment regimens. Stay up to date on recent advances in the multidisciplinary approach to cancer.

2 weeks ago | cancernetwork.com | Rohit Gosain |Rahul Gosain |Emil Lou

April 7, 2025By Panelists discuss how the frontline treatment of pancreatic cancer typically involves chemotherapy regimens such as FOLFIRINOX (leucovorin calcium, fluorouracil, irinotecan hydrochloride, and oxaliplatin) or gemcitabine-based therapies, with decisions guided by tumor characteristics, patient performance status, and treatment goals, aiming to improve survival outcomes and quality of life in newly diagnosed patients.

Aug 21, 2024 | nature.com | Midhun Malla |Timothy Samec |Heinz-Josef Lenz |Emil Lou |Sanjay Goel |Dane C. Olevian

AbstractThe expression of the protein Mesothelin (MSLN) is highly variable in several malignancies, including colorectal cancer (CRC), and high levels are associated with aggressive clinicopathological features and worse patient survival. Colorectal cancer is both a common and deadly cancer; being the third most common in incidence and second most common cause of cancer-related death.